Kymera Therapeutics, Inc.

KYMR

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001815442

C

middle fifth of 305 graded peers in healthcare

rank 152 of 305; percentile 49.7; sampling error 2.8 points; lower is stronger


A B C D E

C, the tortoise




Scoreboard	
Profitability	D percentile 77.2
Solvency	A percentile 12.5
Growth and financing	C percentile 51.9
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.7B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution not computable: distress, fortress balance sheet
Inputs computable	7 of 13
Graded from	filings received through Feb 26, 2026 264 days before the rescan; latest periodic filing 10-Q received Oct 29, 2026
Last close	$125.69 2026-11-16; market equity $10.7B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients' lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Our approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 77.2						
Gross profitability	0.0%	32.8%		96.1	346	2025-12-31
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(5.8%)	(6.7%)	58.3	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 2					
Solvency, sleeve percentile 12.5					
Altman Z double-prime	9.79	0.31	9.2	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	10.47x	2.68x	15.8	781	2025-12-31
Growth and financing, sleeve percentile 51.9					
Revenue growth, three-year compound	(5.7%)	9.6%	81.2	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
NOPAT must exceed $100,000					
Asset growth, three years	42.4%	3.2%	9.4	663	2025-12-31
Net share issuance, one year	25.7%	1.6%	65.2	624	2026-02-20


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 25.7%

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
147	Pediatrix Medical Group, Inc. (MD)	48.0	C	
148	Orasure Technologies Inc. (OSUR)	48.4	C	
149	Repligen Corp. (RGEN)	48.7	C	late filer, fortress balance sheet
150	Zimmer Biomet Holdings, Inc. (ZBH)	49.0	C	
151	Enovis Corp. (ENOV)	49.3	C	
152	Kymera Therapeutics, Inc. (KYMR)	49.7	C	dilution
153	Anika Therapeutics, Inc. (ANIK)	50.0	C	fortress balance sheet
154	ClearPoint Neuro, Inc. (CLPT)	50.3	C	
155	Align Technology Inc. (ALGN)	50.7	C	
156	Amneal Pharmaceuticals, Inc. (AMRX)	51.0	C	
157	Biodesix Inc. (BDSX)	51.3	C	dilution

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	80.8%	(1.7%)	88
Distance from 52-week high	(9.4%)	(31.5%)	74
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(2.2%)	0.5%	39
Book value to price	0.15	0.28	32
Sales to price	0.00	0.36	1
Composite equity issuance, five years	64.5%	13.2%	76
Relative strength against the sector, log excess return	0.42	(0.19)	88
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$373.4M
Operating cash flow, four quarters	-$287.6M
Months of runway	15.6
Days since last periodic filing	19 (10-Q received Oct 29, 2026)
Median daily dollar volume, 63 sessions	$88.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$39.2M	2025-12-31	2026-02-26	10-K	26-073395
2	cost of revenue	us-gaap:CostOfRevenue	$39.2M	2025-12-31	2026-02-26	10-K	26-073395
3	assets	us-gaap:Assets	$1.7B	2025-12-31	2026-02-26	10-K	26-073395
4	net income	us-gaap:NetIncomeLoss	-$311.4M	2025-12-31	2026-02-26	10-K	26-073395
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$232.9M	2025-12-31	2026-02-26	10-K	26-073395
6	assets	us-gaap:Assets	$978.0M	2024-12-31	2026-02-26	10-K	26-073395
7	current assets	us-gaap:AssetsCurrent	$871.2M	2025-12-31	2026-02-26	10-K	26-073395
8	current liabilities	us-gaap:LiabilitiesCurrent	$83.2M	2025-12-31	2026-02-26	10-K	26-073395
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.1B	2025-12-31	2026-02-26	10-K	26-073395
10	operating income	us-gaap:OperatingIncomeLoss	-$349.4M	2025-12-31	2026-02-26	10-K	26-073395
11	book equity	us-gaap:StockholdersEquity	$1.6B	2025-12-31	2026-02-26	10-K	26-073395
12	liabilities	us-gaap:Liabilities	$163.1M	2025-12-31	2026-02-26	10-K	26-073395
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$47.1M	2024-12-31	2026-02-26	10-K	26-073395
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$78.6M	2023-12-31	2026-02-26	10-K	26-073395
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$46.8M	2022-12-31	2025-02-27	10-K	25-028355
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.4M	2025-12-31	2026-02-26	10-K	26-073395
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$194.5M	2024-12-31	2026-02-26	10-K	26-073395

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$12.8M	2024-12-31	2026-02-26	10-K	26-073395
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$102.8M	2023-12-31	2026-02-26	10-K	26-073395
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$34.5M	2023-12-31	2026-02-26	10-K	26-073395
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$153.1M	2022-12-31	2025-02-27	10-K	25-028355
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.8M	2022-12-31	2025-02-27	10-K	25-028355
23	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$8.3M	2025-12-31	2026-02-26	10-K	26-073395
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$311.4M	2025-12-31	2026-02-26	10-K	26-073395
25	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-02-26	10-K	26-073395
26	current assets	us-gaap:AssetsCurrent	$510.3M	2024-12-31	2026-02-26	10-K	26-073395
27	current liabilities	us-gaap:LiabilitiesCurrent	$67.8M	2024-12-31	2026-02-26	10-K	26-073395
28	assets	us-gaap:Assets	$575.8M	2023-12-31	2025-02-27	10-K	25-028355
29	assets	us-gaap:Assets	$603.1M	2022-12-31	2024-02-22	10-K	24-018414
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	81,642,394	2026-02-20	2026-02-26	10-K	26-073395
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	64,944,136	2025-02-21	2025-02-27	10-K	25-028355

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.